Results 251 to 260 of about 234,319 (307)
A study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand. [PDF]
Sci RepOpassathian K +7 more
europepmc +1 more source
Associations of antimicrobial and multidrug resistance in <i>Escherichia coli</i> from the fecal flora and housing environment of calves on dairy farms with atmospheric variables. [PDF]
mSphereBernier Gosselin V +4 more
europepmc +1 more source
Eco-evolutionary responses to plasmid-dependent phage constrain the spread of multidrug-resistance plasmids. [PDF]
ISME JCazares D +11 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Breast Cancer Research and Treatment, 1984
Mutations resulting in a complex phenotype of cross-resistance and collateral-sensitivity are frequently observed in mammalian cell lines. A cell surface 170 000 dalton glycoprotein (P-glycoprotein) has been identified to be intimately associated with this multidrug resistance phenotype.
V, Ling, J, Gerlach, N, Kartner
openaire +2 more sources
Mutations resulting in a complex phenotype of cross-resistance and collateral-sensitivity are frequently observed in mammalian cell lines. A cell surface 170 000 dalton glycoprotein (P-glycoprotein) has been identified to be intimately associated with this multidrug resistance phenotype.
V, Ling, J, Gerlach, N, Kartner
openaire +2 more sources
Anti-Cancer Drugs, 1995
Since we found verapamil as a multidrug resistance (MDR) reversing agent in 1981, many MDR reversing compounds have been reported. This type of drug must have strong effects with little side effects. We recently found MS-209 and PSC-833 as reversing agents.
T, Tsuruo, A, Tomida
openaire +2 more sources
Since we found verapamil as a multidrug resistance (MDR) reversing agent in 1981, many MDR reversing compounds have been reported. This type of drug must have strong effects with little side effects. We recently found MS-209 and PSC-833 as reversing agents.
T, Tsuruo, A, Tomida
openaire +2 more sources
Doxorubicin and multidrug resistance
Current Opinion in Oncology, 1993The circumvention of P-glycoprotein function by pharmacologic agents is a major focus of clinical trials aimed at increasing the cytotoxicity of multidrug resistance-associated drugs, including doxorubicin. The success of this approach will likely depend on the clinical significance of P-glycoprotein expression, which has not yet been elucidated for ...
G D, Kruh, L J, Goldstein
openaire +2 more sources